CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetic medicine company developing disruptive technologies and products based on its proprietary, non-animal recombinant human collagen ...
A breakthrough for biomedical research promises new insight into immunotherapy development and disease modeling. Scientists at The University of Texas Health Science Center at San Antonio have created ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved the first chimeric antigen receptor therapy in 2017, authorizing tisagenlecleucel for treatment ...
Why do 80 to 90% of people infected with COVID-19 experience only mild cases while 10 to 20% face more severe or life-threatening symptoms? Researchers in the lab of Yale's Richard Flavell decided to ...
Immunotherapy harnesses a patient’s own immune system to combat cancer, with numerous benefits compared to conventional treatments such as chemotherapy and surgical removal. 1 Among different ...
Why do 80 to 90% of people infected with COVID-19 experience only mild cases while 10 to 20% face more severe or life-threatening symptoms? Researchers in the lab of Yale’s Richard Flavell decided to ...
A new study further validates the use of humanized BLT mice in the fight to block HIV transmission. The "BLT" name is derived from the fact that these designer mice are created one at a time by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback